Immunic Q2 2020 Earnings Report
Key Takeaways
Immunic reported positive top-line data from its Phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, meeting primary and key secondary endpoints. The company also announced Q2 2020 financial results, including $48.6 million in cash and cash equivalents.
Phase 2 EMPhASIS trial of IMU-838 in RRMS met primary and key secondary endpoints with high statistical significance.
Study showed a statistically significant reduction of 62% and 70% in combined unique active MRI lesions in 45mg and 30mg patient cohorts, respectively, compared to placebo.
Data supports the previously observed favorable safety profile of IMU-838 in the RRMS patient population.
Immunic reported $48.6 million in cash and cash equivalents.
Immunic
Immunic
Forward Guidance
Immunic plans to continue preparing a clinical phase 3 program for IMU-838 in RRMS and anticipates providing a further update on development strategy after a full review of the data. The company is also looking forward to reading out clinical data from the other ongoing phase 2 trials of IMU-838 in COVID-19, primary sclerosing cholangitis and ulcerative colitis in the upcoming months.
Positive Outlook
- Continue to prepare a clinical phase 3 program for IMU-838 in RRMS.
- Provide a further update on development strategy after a full review of the data.
- Read out clinical data from the other ongoing phase 2 trials of IMU-838 in COVID-19.
- Read out clinical data from the other ongoing phase 2 trials of IMU-838 in primary sclerosing cholangitis.
- Read out clinical data from the other ongoing phase 2 trials of IMU-838 in ulcerative colitis.